CL2022002412A1 - Vacuna - Google Patents

Vacuna

Info

Publication number
CL2022002412A1
CL2022002412A1 CL2022002412A CL2022002412A CL2022002412A1 CL 2022002412 A1 CL2022002412 A1 CL 2022002412A1 CL 2022002412 A CL2022002412 A CL 2022002412A CL 2022002412 A CL2022002412 A CL 2022002412A CL 2022002412 A1 CL2022002412 A1 CL 2022002412A1
Authority
CL
Chile
Prior art keywords
viruses
attenuated
relates
present
swine fever
Prior art date
Application number
CL2022002412A
Other languages
English (en)
Spanish (es)
Inventor
Linda Dixon
Ana Reis
Simon Davis
Yuan Jeq Lui
Shinji Ikemizu
Original Assignee
The Pirbright Inst
Univ Kumamoto
The Chancellor Masters And Scholars Of The Univ Of Oxford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003292.6A external-priority patent/GB202003292D0/en
Priority claimed from GBGB2003289.2A external-priority patent/GB202003289D0/en
Priority claimed from GBGB2005878.0A external-priority patent/GB202005878D0/en
Priority claimed from GBGB2005880.6A external-priority patent/GB202005880D0/en
Priority claimed from GBGB2013541.4A external-priority patent/GB202013541D0/en
Application filed by The Pirbright Inst, Univ Kumamoto, The Chancellor Masters And Scholars Of The Univ Of Oxford filed Critical The Pirbright Inst
Publication of CL2022002412A1 publication Critical patent/CL2022002412A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/12011Asfarviridae
    • C12N2710/12021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/12011Asfarviridae
    • C12N2710/12034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/12011Asfarviridae
    • C12N2710/12061Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/12011Asfarviridae
    • C12N2710/12061Methods of inactivation or attenuation
    • C12N2710/12062Methods of inactivation or attenuation by genetic engineering
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/12011Asfarviridae
    • C12N2710/12071Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CL2022002412A 2020-03-06 2022-09-05 Vacuna CL2022002412A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2003292.6A GB202003292D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2003289.2A GB202003289D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2005878.0A GB202005878D0 (en) 2020-04-22 2020-04-22 Vaccine
GBGB2005880.6A GB202005880D0 (en) 2020-04-22 2020-04-22 Vaccine
GBGB2013541.4A GB202013541D0 (en) 2020-08-28 2020-08-28 Vaccine

Publications (1)

Publication Number Publication Date
CL2022002412A1 true CL2022002412A1 (es) 2023-03-03

Family

ID=74870840

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022002416A CL2022002416A1 (es) 2020-03-06 2022-09-05 Vacuna
CL2022002412A CL2022002412A1 (es) 2020-03-06 2022-09-05 Vacuna

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2022002416A CL2022002416A1 (es) 2020-03-06 2022-09-05 Vacuna

Country Status (12)

Country Link
US (3) US20230124042A1 (ko)
EP (3) EP4114453A1 (ko)
JP (2) JP2023516713A (ko)
KR (2) KR20230013017A (ko)
CN (3) CN115397463A (ko)
AU (2) AU2021231402A1 (ko)
BR (2) BR112022016891A2 (ko)
CA (2) CA3170043A1 (ko)
CL (2) CL2022002416A1 (ko)
CO (2) CO2022014152A2 (ko)
MX (2) MX2022010373A (ko)
WO (3) WO2021176234A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024031045A2 (en) * 2022-08-04 2024-02-08 Malcolm Thomas Dominant negative antigen approach for prophylactic and post-infection treatment of swine against african swine fever virus
WO2024057048A1 (en) * 2022-09-12 2024-03-21 Consejo Superior De Investigaciones Científicas Attenuated african swine fever virus and use thereof in vaccine compositions
WO2024110451A1 (en) * 2022-11-22 2024-05-30 Intervet International B.V. Attenuated african swine fever virus and use thereof in vaccine compositions
WO2024110453A1 (en) * 2022-11-22 2024-05-30 Gold Standard Diagnostics Madrid, S.A. Method for differentiating asfv infected from asfv vaccinated animals
CN117224669B (zh) * 2023-07-31 2024-07-30 中国农业科学院兰州兽医研究所 非洲猪瘟病毒mgf360-21r蛋白作为免疫诱导剂或者佐剂的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410971D0 (en) * 2014-06-19 2014-08-06 Pirbright Inst The Vaccine
US9528094B2 (en) * 2014-11-10 2016-12-27 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated African swine fever virus vaccine based in the deletion of MGF genes
CN110551695A (zh) * 2019-08-14 2019-12-10 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 非洲猪瘟病毒四基因缺失弱毒株及其应用

Also Published As

Publication number Publication date
KR20230013016A (ko) 2023-01-26
CN115605223A (zh) 2023-01-13
EP4114455A1 (en) 2023-01-11
EP4114453A1 (en) 2023-01-11
CL2022002416A1 (es) 2023-03-03
CA3170043A1 (en) 2021-09-10
CO2022014256A2 (es) 2022-12-30
MX2022010372A (es) 2023-01-19
AU2021231402A1 (en) 2022-11-03
CO2022014152A2 (es) 2023-02-16
WO2021176234A1 (en) 2021-09-10
BR112022016893A2 (pt) 2023-01-24
US20240293525A1 (en) 2024-09-05
AU2021229654A1 (en) 2022-11-03
CN116133680A (zh) 2023-05-16
EP4114454A1 (en) 2023-01-11
JP2023516713A (ja) 2023-04-20
BR112022016891A2 (pt) 2023-01-24
MX2022010373A (es) 2023-01-19
CN115397463A (zh) 2022-11-25
WO2021176236A1 (en) 2021-09-10
US20230117978A1 (en) 2023-04-20
CA3170058A1 (en) 2021-09-10
WO2021176235A1 (en) 2021-09-10
BR112022016893A8 (pt) 2023-02-28
KR20230013017A (ko) 2023-01-26
JP2023516709A (ja) 2023-04-20
US20230124042A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
CL2022002412A1 (es) Vacuna
EA202193251A1 (ru) Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
PH12018502673A1 (en) Anti-zika virus antibodies and methods of use
EA201990085A1 (ru) Рационально разработанный аттенуированный штамм вируса африканской лихорадки свиней для защиты от заражения исходным вирусным изолятом georgia 2007
CL2016000240A1 (es) Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal.
MX2017013956A (es) Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
MX2019004029A (es) Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
BR112012021650A2 (pt) "parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção de um parvovírus recombinante, e, uso de uma vacina."
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
MX2018006416A (es) Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina.
EA202090693A1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
MX2022008809A (es) Virus de vacuna del sindrome respiratorio y reproductivo porcino.
MX2016002903A (es) Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
EA202091563A1 (ru) Человеческие антитела к гемагглютинину вируса гриппа
EA201401202A1 (ru) ВАКЦИНАЦИЯ РЕСПИРАТОРНЫМ КОРОНАВИРУСОМ СОБАК ДЛЯ ЗАЩИТЫ ОТ ИНФЕКЦИЙ B.Bronchiseptica
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
BR112023019841A2 (pt) Vacina contra vírus da pseudorraiva
MX2021015938A (es) Virus para vacuna contra el síndrome respiratorio y reproductivo porcino.
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
ECSP21039816A (es) Anticuerpos monoclonales antirrábicos y cóctel de estos